Frequentist and Bayesian approaches for a joint model for prostate cancer risk and longitudinal prostate-specific antigen data

Journal of Applied Statistics

Volumn 42, Issue 6, 2015, Pages 1223-1239

  Serrat, Carles ^a   Rué, Montserrat ^b,c   Armero, Carmen ^d   Piulachs, Xavier ^e   Perpiñán, Hèctor ^d   Forte, Anabel ^d   Páez, Álvaro ^f,g   Gómez, Guadalupe ^a  

^a UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^b UNIVERSITY OF LLEIDA   (Spain)

^c Health Services Research Network in Chronic Diseases (REDISSEC)   (India)

^d UNIVERSITY OF VALENCIA   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^g Spanish Branch of the European Randomized Study of Screening for Prostate Cancer ^*

Author keywords

joint models; linear mixed models; prostate cancer screening; relative risk models; shared parameter models

Indexed keywords

EID: 84924912671     PISSN: 02664763     EISSN: 13600532     Source Type: Journal    
DOI: 10.1080/02664763.2014.999032     Document Type: Article

References (47)

1. G.L. Andriole, E.D. Crawford, R.L. Grubb, S.S. Buys, D. Chia, T.R. Church, M.N. Fouad, E.P. Gelmann, P.A. Kvale, D.J. Reding, J.L. Weissfeld, L.A. Yokochi, B. O'Brien, J.D. Clapp, J.M. Rathmell, T.L. Riley, R.B. Hayes, B.S. Kramer, G. Izmirlian, A.B. Miller, P.F. Pinsky, P.C. Prorok, J.K. Gohagan, and C.D. Berg, M.D. for the PLCO Project Team, Mortality results from a randomized prostate-cancer screening trial, New England J. Med. 360 (2009), pp. 1310–1319. doi: 10.1056/NEJMoa0810696
2. M.J. Bayarri and J.O. Berger, The interplay of Bayesian and Frequentist analysis, Statist. Sci. 19 (2004), pp. 58–80. doi: 10.1214/088342304000000116
3. L.J. Brant, S.L. Sheng, C.H. Morrell, G.N. Verbeke, E. Lesaffre, and H.B. Carter, Screening for prostate cancer by using random-effects models, J. R. Statist. Soc: Ser. A (Stat. Soc.) 166 (2003), pp. 51–62. doi: 10.1111/1467-985X.00258
4. H.B. Carter, P.C. Albertsen, M.J. Barry, R. Etzioni, S.J. Freedland, K.L. Greene, L. Holmberg, P. Kantoff, B.R. Konety, M.H. Murad, D.F. Penson, and A.L. Zietman, Early detection of prostate cancer: Aua guideline, Am. Urological Assoc. 190 (2013), pp. 419–426.
5. G. Casella and R.L. Berger, Reconciling Bayesian and Frequentist evidence in the one-sided testing problem, J. American Statist. Assoc. 82 (1987), pp. 106–111. doi: 10.1080/01621459.1987.10478396
6. M.J. Crowther, stjm: Stata module to fit shared parameter joint models of longitudinal and survival data, 2012. http://ideas.repec.org/c/boc/bocode/s457342.html.
7. R. Etzioni, A. Tsodikov, A. Mariotto, A. Szabo, S. Falcon, J. Wegelin, D. diTommaso, K. Karnofski, R. Gulati, D.F. Penson, and E. Feuer, Quantifying the role of PSA screening in the US prostate cancer mortality decline, Cancer Causes Control 19 (2008), pp. 175–181. doi: 10.1007/s10552-007-9083-8
8. C.L. Faucett and D.C. Thomas, Simultaneously modelling censored survival data and repeatedly measured covariates: A Gibbs sampling approach, Stat. Med. 15 (1996), pp. 1663–1685. doi: 10.1002/(SICI)1097-0258(19960815)15:15<1663::AID-SIM294>3.0.CO;2-1
9. F.G. Garre, A.H. Zwinderman, R.B. Geskus, and Y.W. Sijpkens, A joint latent class changepoint model to improve the prediction of time to graft failure, J. R. Statist. Soc: Ser. A (Stat. Soc.) 171 (2008), pp. 299–308.
10. R. Henderson, P. Diggle, and A. Dobson, Joint modelling of longitudinal measurements and event time data, Biostatistics 1 (2000), pp. 465–480. doi: 10.1093/biostatistics/1.4.465
11. B. Holmstrom, M. Johansson, A. Bergh, U.-H. Stenman, G. Hallmans, and P. Stattin, Prostate specific antigen for early detection of prostate cancer: Longitudinal study, BMJ 339 (2009), pp. b3537. doi: 10.1136/bmj.b3537
12. D. Ilic, M.M. Neuberger, M. Djulbegovic, and P. Dahm, Screening for prostate cancer, Cochrane Database Systematic Rev. 1 (2013), pp. CD004720. Available at http://www.ncbi.nlm.nih.gov/pubmed/23440794/.
13. B.A. Inman, J. Zhang, N.D. Shah, and B.T. Denton, An examination of the dynamic changes in prostate-specific antigen occurring in a population-based cohort of men over time, BJU Int. 110 (2012), pp. 375–381. doi: 10.1111/j.1464-410X.2011.10925.x
14. L.Y.T. Inoue, R. Etzioni, E.H. Slate, C. Morrell, and D.F. Penson, Combining longitudinal studies of PSA, Biostatistics 5 (2004), pp. 483–500. doi: 10.1093/biostatistics/kxh003
15. L.Y.T Inoue, R. Etzioni, C. Morrell, and P. Müller, Modeling disease progression with longitudinal markers, J. Am. Statist. Assoc. 103 (2008), pp. 259–270. doi: 10.1198/016214507000000356
16. R.E. Kass, Statistical inference: The big picture, Statist. Sci. 26 (2011), pp. 1–9. doi: 10.1214/10-STS337
17. N.J. Law, J.M.G. Taylor, and H. Sandler, The joint modeling of a longitudinal disease progression marker and the failure time process in the presence of cure, Biostatistics 3 (2002), pp. 547–563. doi: 10.1093/biostatistics/3.4.547
18. S.R. Lele, B. Dennis, and F. Lutscher, Data cloning: Easy maximum likelihood estimation for complex ecological models using Bayesian Markov chain Monte Carlo methods, Ecol. Lett. 10 (2007), pp. 551–563. doi: 10.1111/j.1461-0248.2007.01047.x
19. H. Lin, B.W. Turnbull, C.E. McCulloch, and E.H. Slate, Latent class models for joint analysis of longitudinal biomarker and event process data: Application to longitudinal prostate-specific antigen readings and prostate cancer, J. Am. Statist. Assoc. 97 (2002), pp. 53–65. doi: 10.1198/016214502753479220
20. R.J. Little, Calibrated Bayes: A Bayes/frequentist roadmap, Am. Statist. 60 (2006), pp. 213–223. doi: 10.1198/000313006X117837
21. M. Lujan, A. Paez, A. Berenguer, and J.A. Rodriguez, Mortality due to prostate cancer in the spanish arm of the european randomized study of screening for prostate cancer (ERSPC). Results after a 15-year follow-up, Actas Urológicas Españolas 36 (2012), pp. 403–409.
22. D.J. Lunn, A. Thomas, N. Best, and D. Spiegelhalter, WinBUGS – A Bayesian modelling framework: Concepts, structure, and extensibility, Stat. Comput. 10 (2000), pp. 325–337. doi: 10.1023/A:1008929526011
23. C.H. Morrell, L.J. Brant, S. Sheng, and E.J. Metter, Screening for prostate cancer using multivariate mixed-effects models, J. Appl. Stat. 39 (2012), pp. 1151–1175. doi: 10.1080/02664763.2011.644523
24. A. Neuhaus, T. Augustin, C. Heumann, and D. Daumer, A review on joint models in biometrical research, J. Statist. Theory Pract. 3 (2009), pp. 855–868. doi: 10.1080/15598608.2009.10411965
25. P. Philipson, I. Sousa, P. Diggle, P. Williamson, R. Kolamunnage-Dona, and R. Henderson, Joiner: Joint modelling of repeated measurements and time-to-event data, 2012. Available at http://www.people.fas.harvard.edu/~sfinch/csolve/ou.pdf.
26. J.C. Pinheiro and D.M. Bates, Approximations to the log-likelihood function in the nonlinear mixed-effects model, J. Comput. Graph. Stat. 4 (1995), pp. 12–35.
27. M. Plummer, JAGS: A program for analysis of Bayesian graphical models using Gibbs sampling, 3rd International Workshop on Distributed Statistical Computing (DSC 2003), 2003.
28. R.L. Prentice, Covariate measurement errors and parameter estimation in a failure time regression model, Biometrika 69 (1982), pp. 331–342. doi: 10.1093/biomet/69.2.331
29. C. Proust-Lima and J.M.G. Taylor, Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: A joint modeling approach, Biostatistics 10 (2009), pp. 535–549. doi: 10.1093/biostatistics/kxp009
30. C. Proust-Lima, M. Séne, J.M. Taylor, and H. Jacqmin-Gadda, Joint latent class models for longitudinal and time-to-event data: A review, Stat Methods Med Res 23 (2014), pp. 74–90. doi: 10.1177/0962280212445839
31. D. Rizopoulos, JM: An R package for the joint modelling of longitudinal and time-to-event data, J. Statist. Softw. 35 (2010), pp. 1–33. Available at http://www.jstatsoft.org/v35/i09/.
32. D. Rizopoulos, Dynamic predictions and prospective accuracy in joint models for longitudinal and time-to-event data, Biometrics 67 (2011), pp. 819–829. doi: 10.1111/j.1541-0420.2010.01546.x
33. D. Rizopoulos, Fast fitting of joint models for longitudinal and event time data using a pseudo-adaptive Gaussian quadrature rule, Comput. Stat. Data Anal. 56 (2012), pp. 491–501. doi: 10.1016/j.csda.2011.09.007
34. D. Rizopoulos, Joint Models for Longitudinal and Time-To-Event Data with Applications in R, CRC Press, Boca Ratón, FL, 2012.
35. D. Rizopoulos, JMbayes: Shared parameter models for the joint modeling of longitudinal and time-to-event data using JAGS, WinBUGS, or OpenBUGS. R package 0.4-1, 2013. Available at http://cran.r-project.org/package=JMbayes/.
36. D. Rizopoulos and P. Ghosh, A Bayesian semiparametric multivariate joint model for multiple longitudinal outcomes and a time-to-event, Stat. Med. 30 (2011), pp. 1366–1380. doi: 10.1002/sim.4205
37. M.J. Roobol, H.A. van Vugt, S. Loeb, X. Zhu, M. Bul, Chris H. Bangma, Arno G.L.J.H. van Leenders, E.W. Steyerberg, and F.H. Schröder, Prediction of prostate cancer risk: The role of prostate volume and digital rectal examination in the ERSPC risk calculators, Eur. Urology 61 (2012), pp. 577–583. doi: 10.1016/j.eururo.2011.11.012
38. F. Schröder and M.W. Kattan, The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: A systematic review, Eur. Urology 54 (2008), pp. 274–290. doi: 10.1016/j.eururo.2008.05.022
39. F.H. Schröder, J. Hugosson, M.J. Roobol, T.L.J. Tammela, S. Ciatto, V. Nelen, M. Kwiatkowski, M. Lujan, H. Lilja, M. Zappa, L.J. Denis, F. Recker, A. Páez, L. Määttänen, C.H. Bangma, G. Aus, S. Carlsson, A. Villers, X. Rebillard, T. van der Kwast, P.M. Kujala, B.G. Blijenberg, U.-H. Stenman, A. Huber, K. Taari, M. Hakama, S.M. Moss, H.J. de Koning, and A. Auvinen, M.D. for the ERSPC Investigators, Prostate-cancer mortality at 11 years of follow-up, New Engl. J. Med. 366 (2012), pp. 981–990. doi: 10.1056/NEJMoa1113135
40. J.M.G. Taylor, Y. Park, D.P. Ankerst, C. Proust-Lima, S. Williams, L. Kestin, K. Bae, T. Pickles, and H. Sandler, Real-time individual predictions of prostate cancer recurrence using joint models, Biometrics 69 (2013), pp. 206–213. doi: 10.1111/j.1541-0420.2012.01823.x
41. T. Therneau and P. Grambsch, Modeling Survival Data: Extending the Cox Model, Springer, New York, 2000.
42. A.A. Tsiatis and M. Davidian, Joint modeling of longitudinal and time-to-event data: An overview, Statist. Sin. 14 (2004), pp. 809–834.
43. A.A. Tsiatis, V. Degruttola, and M.S. Wulfsohn, Modeling the relationship of survival to longitudinal data measured with error. Applications to survival and CD4 counts in patients with AIDS, J. Am. Statist. Assoc. 90 (1995), pp. 27–37. doi: 10.1080/01621459.1995.10476485
44. A.J. Vickers, Re: An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection, J. Nat. Cancer Inst. 103 (2011), pp. 1635–1636. doi: 10.1093/jnci/djr353
45. A.J. Vickers, D. Ulmert, A.M. Serio, T. Bjork, Peter T. Scardino, James A. Eastham, G. Berglund, and H. Lilja, The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically-based screening strategy, Int. J. Cancer 121 (2007), pp. 2212–2217. doi: 10.1002/ijc.22956
46. M.S. Wulfsohn and A.A. Tsiatis, A joint model for survival and longitudinal data measured with error, Biometrics 53 (1997), pp. 330–339. doi: 10.2307/2533118
47. M. Yu, N. Law, J. Taylor, and H. Sandler, Joint longitudinal-survival-cure models and their application to prostate cancer, Statist. Sin. 14 (2004), pp. 835–862.